Stephens Investment Management Group LLC Buys Shares of 612,470 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stephens Investment Management Group LLC bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 612,470 shares of the biopharmaceutical company's stock, valued at approximately $4,998,000. Stephens Investment Management Group LLC owned 0.20% of Amicus Therapeutics at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its stake in Amicus Therapeutics by 53.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock valued at $195,000 after buying an additional 8,567 shares during the period. Intech Investment Management LLC grew its stake in shares of Amicus Therapeutics by 59.7% in the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after purchasing an additional 46,633 shares during the last quarter. Norges Bank acquired a new position in shares of Amicus Therapeutics in the 4th quarter worth approximately $29,033,000. Renaissance Technologies LLC grew its stake in shares of Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after purchasing an additional 1,339,316 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock worth $2,850,000 after purchasing an additional 79,602 shares during the last quarter.

Amicus Therapeutics Stock Performance

FOLD stock opened at $6.09 on Monday. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34. The stock has a market cap of $1.88 billion, a P/E ratio of -67.66 and a beta of 0.51. The firm has a 50 day simple moving average of $6.07 and a 200 day simple moving average of $7.76. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on FOLD. The Goldman Sachs Group lowered their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. UBS Group lifted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.